Daily Stock Analysis, FLKS, Flex Pharma Inc, priceseries

Flex Pharma Inc. Daily Stock Analysis
Stock Information
Open
0.62
Close
0.61
High
0.63
Low
0.55
Previous Close
13.69
Daily Price Gain
-13.07
YTD High
14.80
YTD High Date
Jul 23, 2019
YTD Low
0.30
YTD Low Date
Feb 1, 2019
YTD Price Change
0.30
YTD Gain
93.40%
52 Week High
14.80
52 Week High Date
Jul 23, 2019
52 Week Low
0.26
52 Week Low Date
Dec 24, 2018
52 Week Price Change
0.13
52 Week Gain
27.86%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 6. 2017
4.91
Mar 7. 2017
5.42
1 Trading Days
10.39%
Link
LONG
Jun 16. 2017
3.58
Jun 28. 2017
3.91
8 Trading Days
9.18%
Link
LONG
Sep 20. 2017
3.56
Sep 22. 2017
3.75
2 Trading Days
5.48%
Link
LONG
Nov 1. 2017
3.04
Dec 5. 2017
4.06
23 Trading Days
33.63%
Link
LONG
Mar 7. 2018
4.67
Mar 28. 2018
6.38
15 Trading Days
36.65%
Link
Company Information
Stock Symbol
FLKS
Exchange
NasdaqGM
Company URL
http://www.flex-pharma.com
Company Phone
617-874-1821
CEO
Christoph H. Westphal
Headquarters
Massachusetts
Business Address
800 BOYLSTON STREET, 24TH FLOOR, BOSTON, MA 02199
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001615219
About

Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.

Description

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.